Autoimmune disorders result from an overactive immune response of a body working against its own cells. Almost all autoimmune diseases are chronic and have no permanent cure. Over 300 million patients across the globe suffer from these disorders. There are around 80 autoimmune diseases; and the cause of these remains unknown. Women constitute around 70%-75% of all autoimmune patients.
This report analyzes and categorizes the overall market for autoimmune disorders into the submarkets for applications, products, services, and technology. The applications market is further classified into segments catering to systemic autoimmune diseases (that affect several organs of the body) and localized autoimmune diseases (that affect only one organ in the body). The applications market is dominated by the treatment market for rheumatoid arthritis (RA) under systemic disease segment; and by multiple sclerosis (MS) under the localized disease segment. These two diseases account for 75% of the total applications market.
The product market is classified on the basis of autoimmune drugs, diagnostic equipment, and therapeutic and monitoring equipment. Drugs constitute the largest segment of the overall autoimmune products market. Some of the major generic drugs are NSAID, DMARD, biologic DMARD and 5-ASA; some major branded drugs are Avonex, Rebif, Copaxone, and Betaseron. The drugs market, as well as the therapy and monitoring market, is growing due to the chronic nature and the wide prevalence of autoimmune diseases.
Therapy and monitoring form the largest segment of the services market. The technologies used in the treatment of rheumatoid arthritis have a much larger share in comparison to other technologies used for the treatment of psoriasis. Pharmaceutical companies are now focusing on the treatment of autoimmune diseases as these have no permanent cure. A number of government associations and non-profit organizations across the globe are also funding the R&D activities for new drugs and therapies to treat autoimmune diseases. The report provides an in-depth analysis of the applications as well as the products and services market in four geographic regions, namely North America, Europe, Asia-Pacific, and Rest of the World (ROW).
Scope of the report
Rheumatoid arthritis, psoriasis, lupus, multiple sclerosis, inflammatory bowel diseases, type I diabetes, thyroid amongst other diseases.
Consultation and diagnosis, therapy and monitoring, drug development, and other services (such as pharmacokinetic services – what a body does to a drug).
Drugs, therapeutic and diagnostic equipment, and other products (such as bioinformatics).
What makes our reports unique?
Key questions answered
Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies.
Autoimmune Treatment Market
Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.
The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.
The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.
The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.
The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Each segment is analyzed and forecasts are for four geographical regions – North America, Europe, Asia Pacific, and Rest of World (ROW). The North American market includes U.S. and Canada. The European market includes Germany, France, U.K. and other countries in European continent. The major Asia Pacific markets include Japan, Australia, China, India, Singapore and Malaysia. Mexico has been considered in the ROW category along with Middle East, Russia and South Africa.
North America is the largest market for autoimmune treatment with a 42% share of the global market, followed by Europe with a 30% share. However, Asia Pacific with a 20% market share is the fastest-growing market with a 13.3% CAGR from 2009 to 2014
This Report Covers Following Niche Markets : Autoimmune Treatment Market, Pharmaceutical Industry Analysis, Drug Development Market, Clinical Diagnostic Market, Autoimmune Market Research, Autoimmune Market Report, Autoimmune Market Size, Autoimmune Treatment Market Trends